Among different pathogens, opportunistic viral infection caused by EBV is particularly relevant. This gammaherpesvirus, belonging to the Herpesviridae family, may complicate the disease course in different clinical settings by inducing pathological EBV pictures in patients with a defective immunologic response. Our report evaluated EBV-specific T cell responses by IFN- γ ELISPOT assay, which revealed defective EBV specific immunological response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605419 | PMC |
| http://dx.doi.org/10.1016/j.idcr.2021.e01331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intelligent Hierarchical Targeting Near-Infrared Persistent Luminescence Nanosystem for Improved Nuclear Delivery and Simultaneous Visualization/Therapy of EBV-Associated Cancer.
ACS Appl Mater Interfaces
January 2025
Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, China.
Epstein-Barr nuclear antigen 1 (EBNA1), a sequence-specific DNA binding protein of Epstein-Barr virus (EBV), is essential for viral genome replication and maintenance and is therefore an attractive target for the therapeutic intervention of EBV-associated cancers. Several EBNA1-specific inhibitors have demonstrated the ability to block EBNA1 function in vitro, but practical delivery strategies for these inhibitors in vivo are still lacking. Here, we report an intelligent hierarchical targeting theranostic nanosystem (denoted as mZGOCS@MnO-P5) that integrates an azide (N3) terminal dual-targeting peptide (N3-P5), a tumor microenvironment-responsive degradable MnO nanosheet, and a mesoporous ZnGaO:Cr, Sn near-infrared persistent luminescence (NIR-PL) nanosphere (mZGOCS).
View Article and Find Full Text PDFObjectives: Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.
View Article and Find Full Text PDFEpstein-Barr virus-specific T-cell response in pediatric liver transplant recipients: a cross-sectional study by multiparametric flow cytometry.
Front Immunol
November 2024
Clinical Immunology Department, University Hospital La Paz, Madrid, Spain.
Background: Epstein-Barr virus (EBV) specific T-cell response measurement can help adjust immunosuppression in transplant patients with persistent infections. We aim to define T-cell responses against EBV in a cohort of pediatric liver-transplant patients.
Methods: Thirty-eight immunosuppressed pediatric liver-transplant patients (IP) and 25 EBV-seropositive healthy-adult controls (HC) were included in our cross-sectional study.
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.
Front Immunol
September 2024
Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, CA, United States.
Article Synopsis
- Epstein-Barr virus (EBV) is linked to various cancers and diseases, yet despite extensive research, an effective vaccine has not been licensed, largely due to past efforts focusing on a single protein.
- The study presents a new vaccine, MVA-EBV5-2, targeting five EBV entry glycoproteins, demonstrating genetic stability and the ability to produce strong immune responses in animal models.
- Results showed that this vaccine generated higher levels of neutralizing antibodies in mice and rhesus macaques compared to traditional methods, effectively reducing EBV infection in treated models.
Article Synopsis
- α/β T cells are essential for adaptive immunity, with their specificity determined by the unique sequences of their T cell receptor (TCR) chains.
- Traditional bulk TCR sequencing is cost-effective but lacks paired chain data, while single-cell methods provide this data but are expensive and low-throughput.
- The new method, TIRTL-seq, efficiently generates paired TCR libraries from live cells in under 7 hours, enabling extensive profiling of T cell responses with high scalability and reduced costs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!